Leerink analyst Roanna Ruiz raised the firm’s price target on Xeris Biopharma (XERS) to $6 from $5 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma price target raised to $6.50 from $5 at Craig-Hallum
- Xeris Biopharma price target raised to $4 from $3 at Piper Sandler
- Xeris Pharmaceuticals: Strong Growth Potential and Financial Stability Justify Buy Rating
- Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright
- Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook